615 related articles for article (PubMed ID: 19487049)
1. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
2. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.
El Amari EB; Chamot E; Auckenthaler R; Pechère JC; Van Delden C
Clin Infect Dis; 2001 Dec; 33(11):1859-64. PubMed ID: 11692297
[TBL] [Abstract][Full Text] [Related]
3. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
[TBL] [Abstract][Full Text] [Related]
5. [Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].
Pardo Serrano FJ; Tirado Balaguer MD; García Zúñiga ED; Granados Ortega J; Campos Aznar A; Moreno Muñoz R
Rev Esp Quimioter; 2010 Mar; 23(1):20-6. PubMed ID: 20232020
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
[TBL] [Abstract][Full Text] [Related]
7. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005.
Babay HA
Jpn J Infect Dis; 2007 May; 60(2-3):123-5. PubMed ID: 17515646
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.
Raja NS; Singh NN
J Microbiol Immunol Infect; 2007 Feb; 40(1):45-9. PubMed ID: 17332906
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
11. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
12. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
[TBL] [Abstract][Full Text] [Related]
13. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units.
Ong DS; Jongerden IP; Buiting AG; Leverstein-van Hall MA; Speelberg B; Kesecioglu J; Bonten MJ
Crit Care Med; 2011 Nov; 39(11):2458-63. PubMed ID: 21705892
[TBL] [Abstract][Full Text] [Related]
15. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
16. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.
Obritsch MD; Fish DN; MacLaren R; Jung R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4606-10. PubMed ID: 15561832
[TBL] [Abstract][Full Text] [Related]
17. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
Mutnick AH; Rhomberg PR; Sader HS; Jones RN
J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
[TBL] [Abstract][Full Text] [Related]
19. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.
Tam VH; Chang KT; Schilling AN; LaRocco MT; Genty LO; Garey KW
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):279-85. PubMed ID: 19135330
[TBL] [Abstract][Full Text] [Related]
20. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
Lerner SA; Quinn JP
Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
